{
    "2020-04-14": [
        [
            {
                "time": "",
                "original_text": "贝达药业被问询，要求补充说明埃克替尼销量增长的原因及合理性 问询",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "问询",
                        "埃克替尼",
                        "销量增长",
                        "合理性"
                    ],
                    "sentiment_score": -0.2,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：杭州贝昌拟清仓减持不超过1.1%公司股份 减持股份",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "杭州贝昌",
                        "减持",
                        "1.1%股份"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业现1笔大宗交易 共成交1,079.65万元",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "大宗交易",
                        "1,079.65万元"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "一季度业绩预增140%-160% 贝达药业收深交所问询函 问询",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "一季度业绩",
                        "预增",
                        "140%-160%",
                        "问询"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}